PAG-led consortium picks controlling stake in Anjan DrugIllustrative image – not actual.
Private equity fund PAG is picking up a controlling stake in active pharmaceutical ingredient (API) maker Anjan Drug for over USD 70 million.

PAG is partnering with CX Partners and Samara Capital to pick a controlling stake in the Chennai-based Anjan Drug. 

Activity in the API space is attracting attention lately as India tries to veer away from China for its API requirements, and also as the world looks for other options beyond Chinese makers as part of the supply chain shifts. The PAG-led consortium will be paying USD 70-80 million for around 70 percent stake in Anjan Drug.

The acquisition is part of the PAG-led consortium's strategy to create a best-in-class platform for development and production of bulk drug ingredients.

The partnership is the first step in PAG's plan to create preeminent platform for Indian API.

PAG is currently investing out of its USD six billion PAG Asia-III buyout fund and has declared plans to invest up to USD one billion in India over the next few years.

← All latest storiesBack to top →